$0.82
0.00 (-0.18%)
Open$0.81
Previous Close$0.82
Day High$0.92
Day Low$0.79
52W High$2.42
52W Low$0.73
Volume—
Avg Volume186.0K
Market Cap7.15M
P/E Ratio—
EPS$-1.16
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,539.0% upside
Current
$0.82
$0.82
Target
$21.60
$21.60
$19.68
$21.60 avg
$29.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.18M | 3.17M | 3.80M |
| Net Income | -9,212,717 | -6,287,113 | 985.2K |
| Profit Margin | -220.2% | -209.2% | 25.9% |
| EBITDA | -13,995,191 | -10,081,461 | 1.34M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +31.9% | +31.9% | +24.5% |
| Debt/Equity | 0.95 | 0.95 | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |